

(19)



(11)

**EP 3 057 628 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:  
**14.08.2019 Bulletin 2019/33**

(51) Int Cl.:  
**A61M 5/142 (2006.01) A61M 5/158 (2006.01)**

(21) Application number: **14787364.0**

(86) International application number:  
**PCT/US2014/059864**

(22) Date of filing: **09.10.2014**

(87) International publication number:  
**WO 2015/057483 (23.04.2015 Gazette 2015/16)**

**(54) THERAPEUTIC AGENT INJECTION DEVICE**

VORRICHTUNG ZUR INJEKTION VON THERAPIEMITTELN

DISPOSITIF D'INJECTION D'AGENT THÉRAPEUTIQUE

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

- **CHONG, Colin A.**  
Glendale, California 91207 (US)
- **LICKLITER, Hans**  
Canyon Country, California 91351 (US)
- **BIKOVSKY, Rafael**  
Oak Park, California 91377 (US)

(30) Priority: **14.10.2013 US 201314052929**  
**19.09.2014 US 201414491716**

(74) Representative: **Ruschke, Hans Edvard**  
**Ruschke Madgwick Seide & Kollegen**  
Postfach 86 06 29  
81633 München (DE)

(43) Date of publication of application:  
**24.08.2016 Bulletin 2016/34**

(60) Divisional application:  
**19185515.4**

(56) References cited:  
**WO-A1-2006/032692 WO-A1-2006/090148**  
**WO-A1-2006/108809 WO-A1-2008/092959**  
**WO-A2-2004/091692 US-A- 4 755 173**  
**US-A1- 2011 009 823 US-A1- 2011 144 587**

(73) Proprietor: **Medtronic MiniMed, Inc.**  
**Northridge, CA 91325-1219 (US)**

(72) Inventors:  
• **MONTALVO, Susan McConnell**  
**Woodland Hills, California 91364 (US)**

**EP 3 057 628 B1**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**Description****TECHNICAL FIELD**

**[0001]** The technical field of this disclosure is personal medical systems, particularly, therapeutic agent injection devices.

**BACKGROUND OF THE INVENTION**

**[0002]** Certain medical conditions or diseases require that patients intermittently inject a drug or therapeutic agent subcutaneously to maintain the medical condition or disease under control. Multiple daily injections (MDIs) may be required. One such medical condition is diabetes, for which insulin is injected to regulate blood glucose. An estimated twenty-six million people in the United States, or about 8% of the population, have diabetes. This percentage is expected to increase in the near-term as the population ages.

**[0003]** Certain patients are unlikely or unable to follow the drug regimen required to maintain their medical condition under control. Some patients are squeamish about injecting the drug themselves and others suffer adverse effects from repeated injections, such as bruising at the injection site. To accommodate such patients, injection ports have been developed which only require that the patient puncture their skin every few days to install an injection port, rather than injecting with a needle into their skin numerous times a day. Injection ports employ a cannula inserted subcutaneously, and the patient injects the drug into the injection port adhering to their skin rather than directly into their cutaneous tissue.

**[0004]** A new problem arises with damage to the injection port itself. When the injection needle strikes the injection port's cannula, the cannula may be damaged so that the delivery of the drug is no longer controlled. The drug leaks from the damaged portion of the cannula before reaching the required subcutaneous depth. Although a shorter injection needle can be used to attempt to avoid such problems, such needles may not be locally available, limit flexibility in requiring a certain needle length, and provide no assurance that the patient may not still use a longer needle that damages the injection port.

**[0005]** It would be desirable to have a therapeutic agent injection device that would overcome the above disadvantages.

**[0006]** US 2011 / 144587 Stone published 16 June 2011, shows a liquid agent delivery system having top and bottom housing sections to house self contained hydraulic actuator system and cooperating agent delivery system respectively. Flexible membranes on the actuator and delivery systems are mated together such that delivery of fluid can be affected and accurately controlled. A sensor within the hydraulic actuator system is used to detect undue resistance signifying for example a blockage from the delivery system.

**[0007]** US 4,755,173 shows an injection set for insert-

ing a cannula into a patient. A cannula extends from a chamber which is connected to a fluid supply. One face of the injection set is mounted on a patient; on the opposite face is a septum. When the cannula is to be inserted into a patient, a needle is passed through the septum, the chamber and into the cannula providing this with sufficient rigidity that it may puncture the skin of the patient. When the needle is removed through the septum which again seals the chamber; the cannula remains in the patient and is in fluid communication with the fluid supply. Documents WO 2004/091692 A2, WO 2006/090148 A1 and WO 2008/092959 A1 describe prior art infusion devices with introducer ports.

**SUMMARY OF THE INVENTION**

**[0008]** The invention is as defined in claim 1 below. Optional features are set out in the dependent claims.

**SUMMARY OF THE INVENTION**

**[0009]** One aspect of the system described provides an injection device for delivering a therapeutic agent to a patient, the injection device having a body, the body having a patient face and a port face opposite the patient face, the port face having an introducer port including an introducer channel and an injection port including an injection channel, the introducer channel being in fluid communication with the injection channel through a cross channel, the injection channel defining an injection axis; a delivery tube for subcutaneous delivery of the therapeutic agent to the patient, the delivery tube projecting from and being generally perpendicular to the patient face, the delivery tube defining an introducer axis and being in fluid communication with the injection port; and a patch, the patch being attached to the patient face and being operable to adhesively attach to the patient; wherein the injection axis is parallel to the introducer axis.

**[0010]** Another aspect of the system provides an injection device for delivering a therapeutic agent to a patient, the injection device having a body, the body having a patient face and an port face opposite the patient face, the port face having an introducer port including an introducer channel and an injection port including an injection channel, the introducer channel being in fluid communication with the injection channel, the injection channel defining an injection axis; a delivery tube for subcutaneous delivery of the therapeutic agent to the patient, the delivery tube projecting from and being generally perpendicular to the patient face, the delivery tube defining an introducer axis and being in fluid communication with the injection port; and a patch, the patch being attached to the patient face and being operable to adhesively attach to the patient; wherein the body has a first body portion including the port face and a second body portion including the patient face, the first body portion and the second body portion being rotatably connected with a flange, the first body portion and the second body portion

being independently rotatable about the introducer axis.

**[0011]** Another aspect of the described system provides an injection device for delivering a therapeutic agent to a patient, the injection device having a body, the body having a patient face and a port face opposite the patient face, the port face having an introducer port including an introducer channel and an injection port including an injection channel, the introducer channel being in fluid communication with the injection channel, the injection channel defining an injection axis; a delivery tube for subcutaneous delivery of the therapeutic agent to the patient, the delivery tube projecting from and being generally perpendicular to the patient face, the delivery tube defining an introducer axis and being in fluid communication with the injection port; a patch, the patch being attached to the patient face and being operable to adhesively attach to the patient; and a pop-up indicator disposed in the introducer channel, the pop-up indicator having a normal state when pressure in the introducer channel is normal and an alarm state when pressure in the introducer channel exceeds a predetermined value.

**[0012]** The foregoing and other features and advantages of the invention will become further apparent from the following detailed description of the presently preferred embodiments, read in conjunction with the accompanying drawings. The detailed description and drawings are merely illustrative of the invention, rather than limiting the scope of the invention being defined by the appended claims and equivalents thereof.

#### BRIEF DESCRIPTION OF THE DRAWINGS

##### [0013]

**FIGS. 1-5** are perspective, section, perspective, exploded perspective, and perspective views, respectively, of one arrangement of an injection device.

**FIG. 6** is a section perspective view of one arrangement of an injection device.

**FIGS. 7-11** are perspective, perspective, section, section, and perspective section views, respectively, of one embodiment of an injection device made in accordance with the invention.

**FIGS. 12A-12D** are side and section views of needleless pen injectors for use with an injection device.

**FIGS. 13A-13F** are section views of pop-up indicator ports for use with an injection device.

**FIGS. 14A & 14B** are perspective views of one arrangement of an injection device.

**FIGS. 15-20** are front perspective, top side, left side, bottom side, bottom perspective, and detail views, respectively, of one arrangement of a body for an injection device.

**FIG. 21** is a perspective view of one arrangement of an introducer septum for use in an injection device.

**FIG. 22** is a section view of an injection device including the introducer septum of **FIG. 21**.

**FIG. 23** is a perspective view of one arrangement of

a septum for use in an injection device.

**FIGS. 24A & 24B** are top side and section views, respectively, of one arrangement of a septum for use in an injection device.

#### DETAILED DESCRIPTION

**[0014]** **FIGS. 1-5**, in which like elements share like reference numbers, are various views of one arrangement of an injection device. The injection device includes an introducer port along an introducer axis and an injection port along an injection axis, with the injection axis being non-collinear with the introducer axis. In this embodiment, the injection axis is at an angle to and intersects with the introducer axis.

**[0015]** **FIG. 1** is a perspective view of the injection device **100** including a body **110** and a patch **120** attached to the body **110**. The patch **120** is operable to adhesively attach the injection device **100** to a patient (not shown). The body **110** has a port face **112**, with an introducer port **130** and an injection port **140** on the port face **112**. The introducer port **130** is used to place a delivery tube subcutaneously in the patient. The injection port **140** is used by the patient to inject a therapeutic agent, which as defined herein can be any liquid such as a liquid including a therapeutic agent, drug, diagnostic agent, or the like. The body **110** also includes cutouts **160**. Those skilled in the art will appreciate that the introducer port **130** can be too small to be effectively used by a patient for injection, but could be used to inject a therapeutic agent, such as a bolus injection using a mechanically attached device, as desired for a particular application.

**[0016]** **FIG. 2** is a section view of the injection device **100**, the section bisecting the introducer port **130** and the injection port **140**, and includes the introducer axis **134** and injection axis **144**. An axis as defined herein generally follows the centerline of an associated channel through an associated port. The body **110** has a port face **112** and a patient face **114**. A delivery tube **150** for subcutaneous delivery of the therapeutic agent projects from and is generally perpendicular to the patient face **114**. The delivery tube **150** is operably connected to the introducer port **130** and defines an introducer axis **134** along the introducer channel **132**, the delivery tube **150** being in fluid communication with the injection port **140**. The introducer port **130** includes an introducer channel **132**, with an introducer port cover **135** and an introducer septum **136** disposed in the introducer channel **132**. The injection port **140** includes an injection channel **142** defining an injection axis **144** with an injection septum **146** disposed in the injection channel **142**. In one embodiment, the introducer septum **136** and/or the injection septum **146** is self sealing, such that each of the septums block fluid flow through the septum after a needle has been put through the septum then removed, preventing fluid flow from the port. In this embodiment, the injection axis **144** is at an angle to and intersects with the introducer axis **134**. In one example, the delivery tube **150** is

a flexible cannula and a needle hub assembly can be used to place the delivery tube 150 subcutaneously in the patient. In another example, the delivery tube 150 is a rigid needle and the delivery tube 150 can be placed subcutaneously in the patient with or without a needle hub assembly.

[0017] FIG. 3 is a perspective view of the injection device 100 with a needle hub assembly 170. The needle hub assembly 170 includes a needle hub 172 and a needle 174 attached to the needle hub 172. The needle 174 of the needle hub assembly 170 is inserted through the introducer port 130 and through the delivery tube 150 along the introducer axis 134. The needle hub assembly 170 can be used to add rigidity to the delivery tube 150 during implantation when the delivery tube 150 is a flexible cannula.

[0018] FIG. 4 is an exploded perspective view of the injection device with a needle hub assembly. A needle guard 176 disposed around the needle 174 can be used to protect the needle 174 and the delivery tube 150 when the injection device and needle hub assembly are assembled for shipping. The various parts of the injection device and needle hub assembly can be connected by interference fit, adhesive, welding, and/or any other method of attachment suitable for a particular application.

[0019] FIGS. 5A-5C are perspective views of various applications of the injection device. Referring to FIG. 5A, a syringe 190 can be used to deliver a therapeutic agent through the injection port 140 of the injection device 100. The syringe can be a conventional syringe, a standard insulin pen, or a needleless syringe. The needle length of a conventional syringe or standard insulin pen can be of any length because the injection axis is non-collinear with the introducer axis, such that a longer needle does not damage the injection device. In one embodiment, the injection port 140 is adapted to be mateable with the syringe 190, with a socket, fitting, or the like, to increase ease of use. In one example, the injection port 140 is a socket with a socket needle which pierces a foil front end of a needleless syringe when the needleless syringe is seated in the socket. The needleless syringe itself has no needle in this example.

[0020] Referring to FIG. 5B, an on-body injector 192 is mateable with the injection port 140 of the injection device 100 and can be used to deliver a therapeutic agent through the injection port 140. The on-body injector 192 can include a reservoir to hold the therapeutic agent. In one embodiment, the on-body injector 192 can deliver a basal and/or bolus dose of the therapeutic agent.

[0021] Referring to FIG. 5C, an extendable tube 194 can be used to deliver a therapeutic agent through the injection port 140. The extendable tube 194 includes a port connector 195, a tube 196, and an external device fitting 197, all being in fluid communication. The port connector 195 is in fluid communication with the injection port 140 with a needle or mateable fitting to deliver the therapeutic agent through the injection port 140. The external device fitting 197 is connectable to an external de-

vice, such as a wearable insulin pump or an infusion tubing line to a gravity fed container.

[0022] FIG. 6 is a section perspective view of one arrangement of an injection device. In this embodiment, an upper body portion is rotatable about the introducer axis independent of a lower body portion, so that the injection axis can be positioned at a desired rotary angle regardless of the initial placement of the patch on the patient. This allows the patient to select a rotary position for the injection port that is convenient for injection of the therapeutic agent.

[0023] The body of the injection device can have a first body portion including the port face and a second body portion including the patient face, the first body portion and the second body portion being rotatably connected with a flange, the first body portion and the second body portion being independently rotatable about the introducer axis.

[0024] The body 210 of the injection device 200 includes an upper body portion 202 and a lower body portion 204. The upper body portion 202 and lower body portion 204 are rotatably connected with a flange 206 so that the upper body portion 202 and the lower body portion 204 can rotate independently about the introducer axis 234 defined by the delivery tube 250 along the introducer channel 232. The upper body portion 202 has a port face 212 and the lower body portion 204 has a patient face 214. A patch 220 is attached to the patient face 214 and is operable to adhesively attach the injection device 100 to a patient (not shown).

[0025] The delivery tube 250 for subcutaneous delivery of a therapeutic agent projects from and is generally perpendicular to the patient face 214. The delivery tube 250 is operably connected to the introducer port 230, the delivery tube 250 being in fluid communication with the injection port 240. The introducer port 230 includes an introducer channel 232, with an introducer septum 236 disposed in the introducer channel 232. The injection port 240 includes an injection channel 242 defining an injection axis 244 with an injection septum 246 disposed in the injection channel 242.

[0026] The injection axis 244 is non-collinear with the introducer axis 234. In this arrangement, the injection axis 244 is at an angle to and intersects with the introducer axis 234. In one example, the delivery tube 250 is a flexible cannula and a needle hub assembly can be used to place the delivery tube 250 subcutaneously in the patient. In another example, the delivery tube 250 is a rigid needle and the delivery tube 250 can be placed subcutaneously in the patient with or without a needle hub assembly.

[0027] In operation, the patch 220 is attached to the patient and the delivery tube 250 inserted in the patient for subcutaneous delivery of a therapeutic agent. The injection port 240 in the upper body portion 202 can be rotated about the introducer axis 234 even though the lower body portion 204 is at a fixed position on the patient since the lower body portion 204 is attached to the patient

by the patch **220**.

**[0028] FIGS. 7-11**, in which like elements share like reference numbers, are various views of one arrangement of an injection device. The injection device includes an introducer port along an introducer axis and an injection port along an injection axis, with the injection axis being non-collinear with the introducer axis. In this embodiment, the injection axis is parallel to and does not intersect with the introducer axis.

**[0029]** The injection device for delivering a therapeutic agent to a patient can include a body, the body having a patient face and a port face opposite the patient face, the port face having an introducer port including an introducer channel and an injection port including an injection channel, the introducer channel being in fluid communication with the injection channel through a cross channel, the injection channel defining an injection axis; a delivery tube for subcutaneous delivery of the therapeutic agent to the patient, the delivery tube projecting from and being generally perpendicular to the patient face, the delivery tube defining an introducer axis and being in fluid communication with the injection port; and a patch, the patch being attached to the patient face and being operable to adhesively attach to the patient; wherein the injection axis is parallel to the introducer axis.

**[0030]** In some arrangements, the parallel injection axis and introducer axis allows the injection device to function as both an injection device and sensor support. In such arrangements to prevent the sensor from obtaining spurious readings caused by introduction of the therapeutic fluid the introducer channel and injection port would not be in fluid communication. In such arrangements either the introducer channel or the injection port could be adapted to support the insertion and continuous wearing of a sensor. In some arrangements the sensor could be worn for two days before needing to be replaced. In other embodiments the sensor could be worn for up to 14 days before needing to be replaced. Additionally, in some arrangements the sensor would measure glucose values in subcutaneous tissue and associated electronics are able to determine a corresponding blood glucose value.

**[0031] FIG. 7** is a perspective view of the injection device **300** including a body **310** and a patch **320** attached to the body **310**. The patch **320** is operable to adhesively attach the injection device **300** to a patient (not shown). The body **310** has a port face **312**, with an introducer port **330** on the port face **312**. The introducer port **330** is used to place a delivery tube subcutaneously in the patient. In this example, an optional injection cap **302** secured to the body **310** to protect an injection port, which is used by the patient to inject a therapeutic agent.

**[0032] FIG. 8** is a perspective view of the injection device **300** with the optional injection cap removed to expose the injection port **340**. In this example, the body **312** includes threads **306** to secure the optional injection cap to the body and an optional O-ring **304** to seal the area around the injection port **340** when the optional injection

cap is secured to the body.

**[0033] FIG. 9A** is a section view of the injection device **300**, the section bisecting the introducer port **330** and the injection port **340** and including the introducer axis **334** and injection axis **344**. The body **310** has a port face **312** and a patient face **314**. A delivery tube **350** for subcutaneous delivery of the therapeutic agent projects from and is generally perpendicular to the patient face **314**. The delivery tube **350** is operably connected to the introducer port **330** and defines an introducer axis **334** along the introducer channel **332**, the delivery tube **350** being in fluid communication with the injection port **340**. The introducer port **330** includes an introducer channel **332**, with an introducer septum **336** disposed in the introducer channel **332**. The injection port **340** includes an injection channel **342** defining an injection axis **344** with an injection septum **346** disposed over the injection channel **342**. In this embodiment, the injection axis **344** is parallel to and does not intersect with the introducer axis **334**. A cross channel **343** connects the injection channel **342** to the introducer channel **332**. In one example, the delivery tube **350** is a flexible cannula and a needle hub assembly can be used to place the delivery tube **350** subcutaneously in the patient. In another example, the delivery tube **350** is a rigid needle and the delivery tube **350** can be placed subcutaneously in the patient with or without a needle hub assembly.

**[0034] FIG. 9B** is a section view of a different embodiment of injection device **300**, the section bisecting the introduced port **330** and the injection port **340** and including the introducer axis **334** and injection axis **344**. The body **310** includes a port face **312** and a patient face **314**. A delivery tube **350** for subcutaneous delivery of the therapeutic agent projects from and is generally perpendicular to the patient face **314**. The delivery tube **350** is operably connected to the introducer port **330** and defines an introducer axis **334** along the introducer channel **332**, with an introducer septum **336** disposed in the introducer channel **332**. The injection port **340** includes an injection channel **342** defining an injection axis **344** with an injection septum **346** disposed over the injection channel **342**. In this embodiment, the injection axis **344** is parallel and does not intersect with the introducer axis **334**. In this embodiment a delivery tube **350'** is also found operably connected to the injection port **340**. The cross channel **343** found in FIG. 9A is not found in this embodiment enabling a sensor **351** to be placed into the delivery tube **350'** via injection port **340** while therapeutic agents can still be delivered via delivery tube **350** and introducer port **330**. In other embodiments the sensor **351** is placed through delivery tube **350** and introducer port **330** while therapeutic agents are administered via delivery tube **350'** and injection port **340**.

**[0035]** In some embodiments the sensor **351** is a glucose sensor similar to, but not limited to the Enlite Sensor made by Medtronic. In these embodiments the sensor is inserted into the subcutaneous tissue and then connect-

ed to sensor electronics. In some embodiments the sensor electronics are contained within a sealed housing that includes an opening to receive sensor contacts disposed on an end that remains outside the injection device. Physical contact is made between the sensor electronics and the sensor contacts to provide power from the sensor electronics that initiates chemical reactions between the sensor and fluid within the subcutaneous tissue. The sensor electronics housing includes coupling features to removably couple the sensor electronics to the port face 312. In some embodiments the coupling features are compatible screw threads, while in other embodiments the coupling features are quarter turn features or quick release snap type features. The types of coupling features described above are intended to be exemplary and should not be construed as limiting. Additional coupling features can be used that enable quick and secure coupling between the sensor electronics housing and the port face 312.

**[0036]** FIG. 10 is a section view of the injection device 300 with a needle hub assembly 370 and a needle guard 376. The needle hub assembly 370 includes a needle hub 372 and a needle 374 attached to the needle hub 372. The needle 374 of the needle hub assembly 370 is inserted through the introducer port 330 and through the delivery tube 350 along the introducer axis 334. The needle hub assembly 370 can be used to add rigidity to the delivery tube 350 when the delivery tube 350 is a flexible cannula. The needle hub assembly 370 can optionally be used when the delivery tube 350 is a rigid needle. A needle guard 376 disposed around the needle 374 can be used to protect the needle 374 and the delivery tube 350 when the injection device and needle hub assembly are assembled for shipping.

**[0037]** FIG. 11 is a perspective section view of the injection device with an injection adapter assembly. For clarity of illustration, the cross section cut of the injection device 300 in the illustration bisects the introducer port 330 and the injection port 340, and includes the introducer axis 334 and injection axis 344. The cross section cut of the injection adapter assembly 400 in the illustration includes the injection axis 344 and is perpendicular to the section of the injection device 300. The injection adapter assembly 400 screws onto the injection device 300 using the threads 306 on the body 310 to secure the needleless pen injector to the body 310, with the O-ring 304 sealing around the interface between the adapter septum 420 and the injector septum 346. Those skilled in the art will appreciate that the mateable connection securing the needleless pen injector to the body is not limited to threads and can be any mateable connection desired for a particular application.

**[0038]** In this arrangement, the injection adapter assembly 400 is adapted to receive a needleless pen injector (not shown). The adapter body 410 defines a recess 412 adapted to receive a tip of the needleless pen injector. In this example, the needleless pen injector includes threads on its outer diameter complementary to

the adapter threads 414 on the inner diameter of the adapter body 410. The tip of the needleless pen injector is screwed into the recess 412 so that the adapter needle 416 is received in the needleless pen injector, accessing the therapeutic agent contained within the needleless pen injector by piercing a foil on the tip of the needleless pen injector or accessing a pen injector port adapted to receive the adapter needle 416. With the needleless pen injector secured in the injection adapter assembly 400, pressure applied to the therapeutic agent enclosed in the needleless pen injector forces the therapeutic agent through the adapter needle 416 and the adapter septum 420 into the injection device 300, where the therapeutic agent passes through the injector septum 346 into the injection port 340, through the injection channel 342, the cross channel 343, and the delivery tube 350, and into the patient.

**[0039]** Those skilled in the art will appreciate that a variety of interfaces can be used between the needleless pen injector, the injection adapter assembly 400, and the injection device 300. In the embodiment of FIG. 11, the adapter septum 420 and the injector septum 346 are permeable so that the therapeutic agent passes through the adapter septum 420 and the injector septum 346. The septums can be hydrophilic when used with the needleless pen injector to allow the therapeutic agent to pass through. In another arrangement, the injector septum can include a slit valve operable to open on receiving a stub tube at the tip of the needleless pen injector. In yet another arrangement, the injector septum can include a slit valve which is open by a mechanical lever that pushes open and spread the slit valve when the needleless pen injector is received in the injection adapter assembly. In yet another arrangement, the needleless pen injector is interlocked with the injection adapter assembly so that no therapeutic agent can be dispensed from the needleless pen injector until the needleless pen injector is fully engaged with the injection adapter assembly.

**[0040]** FIGS. 12A-12D are various views of needleless pen injectors for use with an injection device. Each of the needleless pen injectors is provided with a manual or automatic pressurization to force the therapeutic agent held within the needleless pen injector into the injection device and patient, once the needleless pen injector has been fully engaged with an injection adapter assembly.

**[0041]** FIG. 12A is a side view of the tip of a needleless pen injector 500 having a barrel 502 to contain a therapeutic agent and optional threads 504 for use with an adapter body having threads on the inner diameter. The end 506 of the needleless pen injector 500 can be adapted to accommodate the particular design of an injection adapter assembly for a particular application. FIG. 12B is a section view of the tip of a needleless pen injector 510 having a barrel 512 to contain a therapeutic agent and a foil 516 across the end of the needleless pen injector 510. The foil 516 can be pierced by an adapter needle in the injection adapter assembly (shown in FIG. 11) to provide fluid communication between the needle-

less pen injector **510** and the injection device through the injection adapter assembly. **FIG. 12C** is a section view of the tip of a needleless pen injector **520** having a barrel **522** to contain a therapeutic agent and a pen port **526** at the end of the needleless pen injector **520**. The pen port **526** can receive an adapter needle in the injection adapter assembly (shown in **FIG. 11**) to open the pen port **526** and provide fluid communication between the needleless pen injector **520** and the injection device through the injection adapter assembly. **FIG. 12D** is a section view of the tip of a needleless pen injector **530** having a barrel **532** to contain a therapeutic agent and a stub tube **536** at the end of the needleless pen injector **530**. The stub tube **536** is operable to open a slit valve on the injector septum of the injection device.

**[0042]** **FIGS. 13A-13F**, in which like elements share like reference numbers, are section views of pop-up indicator ports for use with an injection device.

**[0043]** Because the introducer port and the injection port of the injection device are both in fluid communication with the delivery tube, flow blockage in the delivery tube can cause an increase in pressure at both ports when the patient attempts to inject a therapeutic agent. The flow blockage/pressure increase can be detected by the patient, indicating that the therapeutic agent is not being delivered, with a pop-up indicator port in the port not being used for injection. During injection, the membrane of the pop-up indicator port is close to the body of the injection device under normal conditions, and extends from the body of the injection device when the delivery tube is blocked and the pressure increases above a predetermined pressure.

**[0044]** The pop-up indicator can be disposed in the introducer channel, the pop-up indicator having a normal state when pressure in the introducer channel is normal and an alarm state when pressure in the introducer channel exceeds a predetermined value.

**[0045]** **FIG. 13A & 13B** are section views of a pop-up indicator port **600** with a folded membrane **602** installed as the introducer port. The pop-up indicator port **600** is installed in the introducer channel **632** of the body **610** along the introducer axis **634**, and is in fluid communication with the injection channel. A self-closing port **604** in the membrane **602** allows a needle of a needle hub assembly to pass through the membrane **602** when a needle hub assembly is used to implant the injection device. No self-closing port is required if a needle hub assembly is not used to implant the injection device. Referring to **FIG. 13A**, the pop-up indicator port **600** is in the normal state with normal pressure in the introducer channel **632**, with the membrane **602** folded on itself. Referring to **FIG. 13B**, the pop-up indicator port **600** is in the alarm state due to pressure in the introducer channel **632** exceeding a predetermined value. The pressure occurs when a therapeutic agent is being injected into the injection port, which is in fluid communication with the introducer channel **632**, while the delivery tube is blocked. In the alarm state, the membrane **602** unfolds to extend from the body

**610**.

**[0046]** **FIG. 13C & 13D** are section views of a pop-up indicator port **600** with an accordion membrane **612** installed as the introducer port. Referring to **FIG. 13C**, the pop-up indicator port **600** is in the normal state with normal pressure in the introducer channel **632**, with the membrane **612** pleated like an accordion. Referring to **FIG. 13D**, the pop-up indicator port **600** is in the alarm state due to pressure in the introducer channel **632** exceeding a predetermined value. The pressure occurs when a therapeutic agent is being injected into the injection port, which is in fluid communication with the introducer channel **632**, while the delivery tube is blocked. In the alarm state, the membrane **612** uncompresses the pleats to extend from the body **610**.

**[0047]** **FIG. 13E & 13F** are section views of a pop-up indicator port **600** with a deformable membrane **622** installed as the introducer port. Referring to **FIG. 13E**, the pop-up indicator port **600** is in the normal state with normal pressure in the introducer channel **632**, with the membrane **622** extending across the introducer channel **632**. Referring to **FIG. 13F**, the pop-up indicator port **600** is in the alarm state due to pressure in the introducer channel **632** exceeding a predetermined value. The pressure occurs when a therapeutic agent is being injected into the injection port, which is in fluid communication with the introducer channel **632**, while the delivery tube is blocked. In the alarm state, the material of the membrane **622** deforms under pressure to extend from the body **610**. In another arrangement, the material of the membrane **622** can deform sufficiently to allow the therapeutic agent to leak through the membrane **622**, providing additional indication of the high pressure and delivery tube blockage.

**[0048]** Those skilled in the art will appreciate that the material and dimensions of the parts of the membrane (folds and/or pleats) can be selected as desired for a particular application. In one arrangement, the material is resilient, so that the membrane returns to the normal state after being in the alarm state. In another embodiment, the material is deformable so that the membrane remains extending from the body after the pressure is relieved and the alarm state clears. The extended membrane reminds the patient of the delivery tube blockage and the need to replace the injection device. Exemplary materials for the membrane include silicone rubber or the like.

**[0049]** **FIGS. 14A & 14B**, in which like elements share like reference numbers, are perspective views of one embodiment of an injection device made in accordance with the invention. In this arrangement, the injection device includes a tube with an external device fitting, so that the injection device can be placed in a remote location and attached to an injection pump.

**[0050]** **FIG. 14A** is a perspective view of the injection device **700** in a stored configuration, the injection device **700** including a body **710** and a patch **720** attached to the body **710**. The patch **720** is operable to adhesively

attach the injection device **700** to a patient (not shown). The body **710** has a groove **702** around its outer circumference operable to receive tube **794** in the stored configuration. One end of the tube **794** is in fluid communication with an injection port (not shown) of the injection device **700** to deliver a therapeutic agent into the body of a patient. The other end of the tube **794** is in fluid communication with the external device fitting **797**, which can be extended to a convenient location when the injection device **700** is in a difficult to access location or which can be connected to an injection pump (not shown). In this example, the body **710** includes a fitting receiver **704** operable to receive and store the external device fitting **797** when the injection device **700** is in the stored configuration with the tube **794** wrapped around the body **710**. **FIG. 14B** is a perspective view of the injection device **700** in a deployed configuration, with the external device fitting **797** uncoupled from the fitting receiver **704** and the tube **794** uncoiled from the groove **702** in the body **710**. In operation, the injection device **700** can be placed on a remote location on the body of the patient, such as a remote location not normally accessible for injection by conventional means, and the tube **794** extended to allow convenient connection to an injection pump.

**[0051]** **FIGS. 15-20**, in which like elements share like reference numbers, are various views of one arrangement of a body for an injection device. The body includes cutouts to provide inspection and ventilation at the attachment point of the injection device to the patient.

**[0052]** The single piece body for an injection device can include a planar deck having a patient face, the planar deck having cutouts around and through the planar deck, the planar deck including a delivery tube port on the patient face; a port segment attached opposite the patient face of the planar deck, the port segment including an introducer port including an introducer channel and an injection port including an injection channel the introducer channel being in fluid communication with the injection channel and the delivery tube port; and attachment projections protruding from the patient face. In one arrangement, the attachment projections are operable for plastic welding.

**[0053]** The single piece body can be used with an injection device for delivering a therapeutic agent to a patient including the single piece body. The injection device further includes a delivery tube for subcutaneous delivery of the therapeutic agent to the patient, the delivery tube projecting from and being generally perpendicular to the patient face, the delivery tube being in fluid communication with the injection port; and a patch, the patch being plastically welded to the attachment projections and being operable to adhesively attach to the patient.

**[0054]** **FIGS. 15 & 16** are a front perspective view and a top side view, respectively, of a body **810** including a port face **812**. The port face **812** includes an introducer port **830** and an injection port **840**. The body **810** has a generally planar deck **804** with cutouts **860** spaced

around and passing through the planar deck **804**. The body **810** also has a port segment **806** rising above the planar deck **804** and including the introducer port **830** and an injection port **840**. The body **810** is a single piece body, which is defined herein as a body formed as a single piece and is not a group of separate pieces assembled to form the body.

**[0055]** **FIG. 17** is a left side view of the body **810**. The patient face **814** is opposite the port face **812** on the planar deck **804** and is operable to connect the body **810** to a patch (not shown) to adhesively attach the injection device to a patient. In this arrangement, the patient face **814** of the planar deck **804** includes a number of attachment projections **820** (in this example, the attachment projections **820** being bumps) protruding from the planar deck **804** to allow a patch to be plastically welded to the body **810**. Those skilled in the art will appreciate that different attachment projections, such as truncated pyramids, bumps, radial lines, concentric rings, or the like, can be selected as desired for a particular application. In yet another arrangement, the patch can be attached to the body **810** with an adhesive.

**[0056]** **FIGS. 18 & 19** are a bottom side view and a bottom perspective view, respectively, of the body **810**. The attachment projections **820** are arranged around the outer circumference **823** of the patient face **814**, around an inner circle **822** about a delivery tube port **825** on the introducer axis **834**, and along diameter segments **824** between the outer circumference **823** and the inner circle **822** which follow the length of the port segment. In this example, the attachment projections **820** are truncated pyramids.

**[0057]** **FIG. 20** is a section view of the planar deck **804** of the body **810** along the outer circumference through the attachment projections **820**. In this example, the body **810** is plastically welded to a patch **830**, which is attached to the skin **832** of a patient. The attachment projections **820** are deformed from the truncated pyramid to a flattened, rounded shape from welding the attachment projections **820** to the patch **830** at each fixation point **836**. In this example, the tips of the attachment projections **820** are welded into the patch **830**, i.e., the tips of the attachment projections rest below the surface of the patch at the fixation points **836** where the attachment projections **820** join the patch **830**. In cross section through adjacent attachment projections **820**, the patient face **814** and the patch **830** define a ventilation gap **838** to provide ventilation and air circulation between the planar deck **804** and the patch **830**, cooling the skin **832** across the patch **830** from the ventilation gap **838**.

**[0058]** Those skilled in the art will appreciate that the design of the patch **830** can be selected as desired for a particular application. The patch can be made of any biocompatible material with biocompatible adhesive operable to hold the weight of the injection device to the skin for a predetermined number of days. The patch design also needs to account for ventilation and circulation between the patch and the skin. In one example, the patch

is a continuous sheet of adhesive material. In another example, the patch is a mesh sheet of adhesive material including perforations. In yet another example, the patch is a continuous sheet of adhesive material with holes cut into the continuous sheet. The holes can align with features of the body of the injection device, such as the cutouts, as desired. The holes can optionally be the same size as the cutouts. In yet another example, the patch is a continuous sheet of adhesive material with holes cut into the continuous sheet, and mesh applied across the holes. In yet another example, the patch can be made of a transparent material to allow the condition of the skin around and below the injection device to be monitored. In one example, adhesive patches are constructed of pressure sensitive acrylic-based adhesives with non-woven polyester backings.

[0059] Those skilled in the art will further appreciate that the design of the body of the injection device can be selected as desired for a particular application. In one example, the number and position of the cutouts in the planar deck can be selected to provide ventilation to the skin while maintaining sufficient rigidity for the planar deck. In another example, the number and position of the cutouts can be selected to allow observation of the condition of the skin around and below the injection device. In yet another example, the body of the injection device can be made of a transparent material to allow the condition of the skin around and below the injection device to be monitored. This is particularly useful when the patch includes holes or is made from a transparent material. Exemplary materials for the body of the injection device include polycarbonate, acrylic, or the like. In one embodiment, one or more optical elements can be molded into the body of the injection device to magnify the area or areas of interest.

[0060] FIGS. 21-24 are various arrangements of septums for use in an injection device. The septums can be disposed in the injection device channels. In one arrangement, the septum is self sealing to block fluid flow through the septum after a needle has been put through the septum then removed, preventing fluid flow through the port connected to the channel.

[0061] FIG. 21 is a perspective view of one arrangement of an introducer septum for use in an injection device. Here, the introducer septum is irregular-shaped, i.e., the introducer septum has an irregular shape. The introducer septum 900 includes a number of legs 902 to secure the introducer septum 900 in the introducer channel.

[0062] FIG. 22 is a section view of an injection device : including the introducer septum of FIG. 20. The section bisects the introducer port 930 and the injection port 940, and includes the introducer axis 934 and injection axis 944. The delivery tube 950 is operably connected to the introducer port 930 and defines an introducer axis 934, the delivery tube 950 being in fluid communication with the injection port 940. The introducer port 930 includes an introducer channel 932, with an introducer port cover

935 and the introducer septum 900 disposed in the introducer channel 932. The introducer septum 900 is secured in the introducer channel 932 of the injection device 901 by legs 902. The injection port 940 includes an injection channel 942 defining an injection axis 944 with an injection septum 946 disposed in the injection channel 942. The injection channel 942 is in fluid communication with the delivery tube 950 through a septum connection channel 904 in the introducer septum 900. The introducer septum 900 both connects the injection port 940 to the delivery tube 950 and fills extra space within the introducer channel 932 to avoid an unnecessary amount of therapeutic agent from collecting in the introducer channel 932.

[0063] FIG. 23 is a perspective view of one arrangement of a septum for use in an injection device. In this embodiment, the septum is barrel-shaped. The barrel-shape septum 980 can be used as an introducer septum or an injection septum as desired for a particular application.

[0064] FIGS. 24A & 24B are top side and A-A section views, respectively, of one arrangement of a septum for use in an injection device.

In this arrangement, the septum is dome-shaped. The dome septum 990 can be used as an introducer septum or an injection septum as desired for a particular application.

## Claims

1. An injection device (100, 300) for delivering a therapeutic agent to a patient, the injection device (100) comprising:

a body (110, 310) having a patient face (114, 314) and a port face (112, 312) opposite the patient face (114, 314), the port face (112, 312) having an introducer port (130, 330) including an introducer channel (132, 332) and an injection port (140, 340) including an injection channel (142, 342), the injection channel (142, 342) defining an injection axis (144, 344);

a first delivery tube (350) for subcutaneous delivery of the therapeutic agent to the patient, the delivery tube (350) projecting from and being generally perpendicular to the patient face (314), the first delivery tube (350) defining an introducer axis (334) and being in fluid communication with the introducer port (330);

a second delivery tube (350') projecting from and being generally perpendicular to the patient face (314), the second delivery tube (350') defining the injection axis (344) and being in fluid communication with the injection port (130, 340);

a patch (120, 320) attached to the patient face (114, 314) and operable to adhesively attach to

- the patient;  
 wherein the injection port (140, 340) is defined to accommodate a sensor (351);  
 wherein the injection axis (344) is parallel to and does not intersect with the introducer axis (334).
2. The injection device of claim 1 wherein the introducer port (330) includes an introducer septum (336) disposed in the introducer channel (332).
3. The injection device of claim 1 wherein the injection port (340) includes an injection septum (346) disposed over the injection channel (342).
4. The injection device of claim 1 wherein the sensor (351) is a glucose sensor
5. The injection device of claim 1 wherein the sensor is connected to sensor electronics.
6. The injection device of claim 5 wherein the sensor electronics are contained within a sealed housing.
7. The injection device of claim 6 wherein the sensor electronics housing includes coupling features to removably couple the sensor electronics to the port face (312).

#### Patentansprüche

1. Injektionsvorrichtung (100, 300) zum Verabreichen eines Therapeutikums an einen Patienten, wobei die Injektionsvorrichtung (100) Folgendes umfasst:

einen Körper (110, 310) mit einer Patientenseite (114, 314) und einer der Patientenseite (114, 314) gegenüberliegenden Öffnungsseite (112, 312), wobei die Öffnungsseite (112, 312) eine Einführöffnung (130, 330) einschließlich eines Einführkanals (132, 332) und eine Injektionsöffnung (140, 340) einschließlich eines Injektionskanals (142, 342) aufweist, wobei der Injektionskanal (142, 342) eine Injektionsachse (144, 344) definiert;

ein erstes Verabreichungsrohr (350) zur subkutanen Verabreichung des Therapeutikums an den Patienten, wobei das Verabreichungsrohr (350) von der Patientenseite (314) hervorsteht und allgemein senkrecht dazu ist, wobei das erste Verabreichungsrohr (350) eine Einführachse (334) definiert und mit der Einführöffnung (330) in Fluidverbindung steht;

ein zweites Verabreichungsrohr (350'), das von der Patientenseite (314) hervorsteht und allgemein senkrecht dazu ist, wobei das zweite Verabreichungsrohr (350') die Injektionsachse (344) definiert und mit der Injektionsöffnung

(130, 340) in Fluidverbindung steht; eine Auflage (120, 320), die an der Patientenseite (114, 314) befestigt ist und geeignet ist, um klebend an dem Patienten befestigt zu sein; wobei die Injektionsöffnung (140, 340) dazu definiert ist, einen Sensor (351) aufzunehmen; wobei die Injektionsachse (344) parallel zu der Einführachse (334) ist und sich nicht mit ihr schneidet.

2. Injektionsvorrichtung nach Anspruch 1, wobei die Einführöffnung (330) ein Einführseptum (336) beinhaltet, das in dem Einführkanal (332) angeordnet ist.
3. Injektionsvorrichtung nach Anspruch 1, wobei die Injektionsöffnung (340) ein Injektionsseptum (346) beinhaltet, das über dem Injektionskanal (342) angeordnet ist.
4. Injektionsvorrichtung nach Anspruch 1, wobei der Sensor (351) ein Glukosesensor ist.
5. Injektionsvorrichtung nach Anspruch 1, wobei der Sensor mit Sensorelektronik verbunden ist.
6. Injektionsvorrichtung nach Anspruch 5, wobei die Sensorelektronik innerhalb eines abgedichteten Gehäuses enthalten ist.
7. Injektionsvorrichtung nach Anspruch 6, wobei das Sensorelektronikgehäuse Kopplungsmerkmale beinhaltet, um die Sensorelektronik lösbar mit der Öffnungsseite (312) zu koppeln.

#### Revendications

1. Dispositif d'injection (100, 300) pour administrer un agent thérapeutique à un patient, le dispositif d'injection (100) comprenant :

un corps (110, 310) ayant une face patient (114, 314) et une face orifice (112, 312) opposée à la face patient (114, 314), la face orifice (112, 312) ayant un orifice d'introduction (130, 330) incluant un canal d'introduction (132, 332) et un orifice d'injection (140, 340) incluant un canal d'injection (142, 342), le canal d'injection (142, 342) définissant un axe d'injection (144, 344) ; un premier tube d'administration (350) pour l'administration sous-cutanée de l'agent thérapeutique au patient, le tube d'administration (350) faisant saillie à partir de la face patient (314) et étant généralement perpendiculaire à la face patient (314), le premier tube d'administration (350) définissant un axe d'introduction (334) et étant en communication fluide avec l'orifice d'introduction (330) ;

- un deuxième tube d'administration (350') faisant saillie à partir de la face patient (314) et étant généralement perpendiculaire à la face patient (314), le deuxième tube d'administration (350') définissant l'axe d'injection (344) et étant en communication fluidique avec l'orifice d'injection (130, 340) ; 5
- un patch (120, 320) fixé à la face patient (114, 314) et pouvant fonctionner pour se fixer de manière adhésive au patient ; 10
- dans lequel l'orifice d'injection (140, 340) est défini pour recevoir un capteur (351) ;
- dans lequel l'axe d'injection (344) est parallèle à l'axe d'introduction (334) et ne se croise pas avec l'axe d'introduction (334). 15
2. Dispositif d'injection selon la revendication 1 dans lequel l'orifice d'introduction (330) inclut un septum d'introduction (336) disposé dans le canal d'introduction (332). 20
3. Dispositif d'injection selon la revendication 1 dans lequel l'orifice d'injection (340) inclut un septum d'injection (346) disposé sur le canal d'injection (342). 25
4. Dispositif d'injection selon la revendication 1 dans lequel le capteur (351) est un capteur de glucose.
5. Dispositif d'injection selon la revendication 1 dans lequel le capteur est connecté à une électronique de capteur. 30
6. Dispositif d'injection selon la revendication 5 dans lequel l'électronique de capteur est contenue à l'intérieur d'un boîtier scellé. 35
7. Dispositif d'injection selon la revendication 6 dans lequel le boîtier d'électronique de capteur inclut des éléments de couplage pour coupler de manière amovible l'électronique de capteur à la face orifice (312). 40

45

50

55





FIG. 1







FIG. 3






FIG. 5A




FIG. 5B




FIG. 5C




FIG. 6




FIG. 7




FIG. 8




FIG. 9A




FIG. 9B




FIG. 10




FIG. 11




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D




FIG. 13E




FIG. 13F




FIG. 14A




FIG. 14B




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24A




FIG. 24B

**REFERENCES CITED IN THE DESCRIPTION**

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

**Patent documents cited in the description**

- US 2011144587 A [0006]
- US 4755173 A [0007]
- WO 2004091692 A2 [0007]
- WO 2006090148 A1 [0007]
- WO 2008092959 A1 [0007]